The impact of peroxisome proliferator-activated receptor-γ activating angiotensin receptor blocker on outcomes of patients receiving immunotherapy

Article Cardiac & Cardiovascular Systems

Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer

Cho-Han Chiang et al.

Summary: This study demonstrates that SGLT2 inhibitors can reduce the incidence of heart failure and prolong overall survival in patients with diabetes mellitus and cancer.

HEART (2023)

Add to Collection

Article Oncology

Effect of metformin on outcomes of patients treated with immune checkpoint inhibitors: a retrospective cohort study

Cho-Han Chiang et al.

Summary: Metformin has been associated with improved survival outcomes in cancer patients undergoing chemotherapy, but its impact on patients receiving immune checkpoint inhibitors (ICIs) is unknown. A retrospective cohort study in Taiwan found that metformin users had longer overall survival (OS) and progression-free survival (PFS) compared to non-users. Furthermore, the use of metformin was associated with a lower risk of mortality and disease progression.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2023)

Add to Collection

Article Oncology

The Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Outcomes of Patients Treated with Immune Checkpoint Inhibitors: a Retrospective Cohort Study

C. H. Chiang et al.

Summary: This study found that the use of RAASi is associated with improved overall survival, progression-free survival, and clinical benefit rates in patients receiving immune checkpoint inhibitors.

CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Impact of renin-angiotensin system inhibitors on outcomes in patients with metastatic renal cell carcinoma treated with immune-checkpoint inhibitors

Pier Vitale Nuzzo et al.

Summary: This multicenter retrospective study suggests that the concurrent use of renin-angiotensin system inhibitors (RASi) with immune-checkpoint inhibitors (ICI) may improve overall survival and time-to-treatment failure in patients with metastatic renal cell carcinoma (mRCC). These findings provide a rationale for future prospective randomized studies exploring the efficacy of combining ICI and RASi in mRCC patients.

CLINICAL GENITOURINARY CANCER (2022)

Add to Collection

Article Oncology

Renin-angiotensin-aldosterone system inhibitors and survival in patients with hypertension treated with immune checkpoint inhibitors

Zsofia D. Drobni et al.

Summary: This retrospective study investigated the association between the use of renin-angiotensin-aldosterone system (RAAS) inhibitors and outcomes in patients treated with immune checkpoint inhibitors (ICIs). The results showed that hypertension patients who concomitantly took a RAAS inhibitor during ICI therapy had better overall survival. This benefit was particularly significant among patients with gastrointestinal and genitourinary cancers.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Efficacy of cationic amphiphilic antihistamines on outcomes of patients treated with immune checkpoint inhibitors

Cho-Han Chiang et al.

Summary: This study aimed to evaluate the effect of cationic amphiphilic antihistamines on patients receiving immune checkpoint inhibitors. The results showed that patients who received cationic amphiphilic antihistamines had significantly improved overall survival and progression-free survival. These survival benefits were observed regardless of the generation of cationic amphiphilic antihistamines.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

The incidence and risk of cardiovascular events associated with immune checkpoint inhibitors in Asian populations

Cho-Han Chiang et al.

Summary: Among Asians, the use of immune checkpoint inhibitors is associated with an increased risk of major adverse cardiovascular events, particularly ischemic stroke and pulmonary embolism. The risk of major adverse cardiovascular events is 60% higher in immune checkpoint inhibitor users, with an incidence rate ratio of 2.1 compared to non-users. Additionally, immune checkpoint inhibitors are independently associated with an increased risk of ischemic stroke and pulmonary embolism.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index

Sebastiano Buti et al.

Summary: Corticosteroids, antibiotics, and proton-pump inhibitors were found to have a significant impact on the outcomes of patients treated with ICIs. A drug-based prognostic score was proposed based on these medications, which proved to be valuable in stratifying patients and could be useful in routine practice and clinical trials involving ICIs.

EUROPEAN JOURNAL OF CANCER (2021)

Add to Collection

Article Oncology

Angiotensin Blockade Modulates the Activity of PD1/L1 Inhibitors in Metastatic Urothelial Carcinoma

Rohit K. Jain et al.

Summary: The study suggests that concurrent use of ACEIs/ARBs and PD1/L1 inhibitors may have potential additive or synergistic effects in patients with metastatic urothelial carcinoma. This combination therapy could potentially downregulate transforming growth factor beta and enhance treatment outcomes.

CLINICAL GENITOURINARY CANCER (2021)

Add to Collection

Article Oncology

The Impact of VEGF Inhibition on Clinical Outcomes in Patients With Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy: A Retrospective Cohort Study

Keiko Tanimura et al.

Summary: This study found that patients who had received anti-VEGF therapy prior to ICIs had shortened progression-free survival and decreased overall response rate to ICI treatment. On the other hand, patients who received anti-VEGF therapy after ICI treatment showed increased survival, especially those who had received anti-VEGF therapy before ICI therapy. Further investigation is needed to understand the role of VEGF inhibition in altering clinical outcomes after immunotherapy in NSCLC patients.

FRONTIERS IN ONCOLOGY (2021)

Add to Collection

Article Oncology